Mirataz
mirtazapine
Table of contents
Overview
Mirataz is a medicine used to produce an increase in bodyweight in cats with long-term conditions known to cause poor appetite and weight loss. It contains the active substance mirtazapine.
Authorisation details
Product details | |
---|---|
Name |
Mirataz
|
Agency product number |
EMEA/V/C/004733
|
Active substance |
mirtazapine
|
International non-proprietary name (INN) or common name |
mirtazapine
|
Species |
Cats
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QN06AX11
|
Publication details | |
---|---|
Marketing-authorisation holder |
Dechra Regulatory B.V.
|
Revision |
2
|
Date of issue of marketing authorisation valid throughout the European Union |
10/12/2019
|
Contact address |
Handelsweg 25 |
Product information
15/01/2021 Mirataz - EMEA/V/C/004733 - IB/0003/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Psychoanaleptics
-
Antidepressants in combination with psycholeptics
Therapeutic indication
For bodyweight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.